Possible new markers in trophoblastic diseases

Inaba, Noriyuki; Ishige, Hideo; Ijichi, M; Satoh, Naomi; Katoh, Takako; Sekiya, Souei; Shirotake, S; Ohkawa, Reiko; Takamizawa, H; Nitoh, Akio; Renk, T.; Bohn, H.

doi:10.1016/0002-9378(82)90488-4

Cited by 14 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detection of PP11 in several malignant cells (3)(4)(5) can instead suggest that its deregulated expression may be associated with oncogenesis. In this regard, we find intriguing the parallel between the physiological expression of PP11 in syncytiotrophoblastic cells and its aberrant expression in tumoral cells; both cell types are characterized by the capacity to invade the adjacent tissues.…”

Section: Discussionmentioning

confidence: 99%

“…Unlike PP8 and PP9, which were found in relatively high concentrations in all tissues analyzed, PP10, PP11, and PP12 were supposed to be specific to the placentas, since they could not be detected in extracts of other human tissues (1,2). Interestingly, it was shown that the placenta-specific proteins were also expressed in several tumor tissues; PP11 was detected in 66.7% of the analyzed mucinous cystadenocarcinomas and in 57.1% of serous cystadenocarcinomas tested, whereas it was not found in normal ovaries (3). Moreover, PP11 was also found in 47% of all breast cancers examined (4) and in 38% of all testicular and gastric cancers studied (5).…”

mentioning

confidence: 94%

See 1 more Smart Citation

The Tumor Marker Human Placental Protein 11 Is an Endoribonuclease

Laneve

Gioia

Ragno

et al. 2008

Journal of Biological Chemistry

View full text Add to dashboard Cite

Human PP11 (placental protein 11) was previously described as a serine protease specifically expressed in the syncytiotrophoblast and in numerous tumor tissues. Several PP11-like proteins were annotated in distantly related organisms, such as worms and mammals, suggesting their involvement in evolutionarily conserved processes. Based on sequence similarity, human PP11 was included in a protein family whose characterized members are XendoU, a Xenopus laevis endoribonuclease involved in small nucleolar RNA processing, and Nsp15, an endoribonuclease essential for coronavirus replication. Here we show that the bacterially expressed human PP11 displays RNA binding capability and cleaves single stranded RNA in a Mn 2؉ -dependent manner at uridylates, to produce molecules with 2,3-cyclic phosphate ends. These features, together with structural and mutagenesis analyses, which identified the potential active site residues, reveal striking parallels to the amphibian XendoU and assign a ribonuclease function to PP11. This newly discovered enzymatic activity places PP11-like proteins in a completely new perspective. PP11 (placental protein 11) is one of the five glycoproteins (together with PP8, PP9, PP10, and PP12) that were first isolated from aqueous extracts of human term placentas in the 1980s. Unlike PP8 and PP9, which were found in relatively high concentrations in all tissues analyzed, PP10, PP11, and PP12 were supposed to be specific to the placentas, since they could not be detected in extracts of other human tissues (1, 2). Interestingly, it was shown that the placenta-specific proteins were also expressed in several tumor tissues; PP11 was detected in 66.7% of the analyzed mucinous cystadenocarcinomas and in 57.1% of serous cystadenocarcinomas tested, whereas it was not found in normal ovaries (3). Moreover, PP11 was also found in 47% of all breast cancers examined (4) and in 38% of all testicular and gastric cancers studied (5). These results suggested

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 94%

The Tumor Marker Human Placental Protein 11 Is an Endoribonuclease

Laneve

Gioia

Ragno

et al. 2008

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Inaba et al have investigated the localization of PP5, PP10, PPll, and PP12 in trophoblastic tumors and ovarian adenocarcinomas by using immunohistochemical methods [9,11,13,14]. These proteins have been found to be associated with the carcinoma of the breast and digestive system [3,10,12,15].…”

Section: Introductionmentioning

confidence: 98%

Enzyme immunoassay for placental protein 4 (PP4) and its possible diagnostic significance in patients with genital tract cancer

Ota

Inaba

Shirotake

et al. 1990

Arch Gynecol Obstet

View full text Add to dashboard Cite

We have established an enzyme immunoassay for placental protein 4 (PP4), by using avidin-biotin binding reaction, and set its normal range below 10.9 ng/ml (mean + 2 sigma). Throughout the menstrual cycle, the serum PP4 profile was similar to that of serum progesterone. In the follicular and ovulatory phase, PP4 remained relatively low, with the mean levels of 1.5 ng/ml and 1.8 ng/ml, respectively. In the luteal phase, the mean level was 3.2 ng/ml. In normal pregnancy, serum PP4 levels were low irrespective of gestational age, with a mean level of 3.0 ng/ml. There was only one case in which the serum PP4 level over 10.9 ng/ml. Mean serum PP4 levels and the frequencies of elevated serum PP4 levels were respectively 6.3 ng/ml and 11% in patients with benign ovarian neoplasms, 4.7 ng/ml and 6% in patients with endometriosis, and 5.5 ng/ml and 18% in patients with uterine myomata. The frequency of raised PP4 levels was 48% and the mean value was 13.3 ng/ml in patients with endometrial carcinoma, and the values were 44% and 13.4 ng/ml respectively in patients with cervical carcinoma. In patients with ovarian malignancy, the respective values were 15% and 7.0 ng/ml. The results did not relate to clinical stages of disease (FIGO), while the frequencies of elevated serum PP4 in patients with uterine carcinoma was over 40% in stage I diseases. Compared with other tumor markers such as carcino-embryonic antigen (CEA), tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125), PP4 seems to be more promising as a marker of endometrial carcinoma.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…PPAN knockdown is also associated with mitochondrial damage and stimulation of autophagy (Dannheisig et al, 2019). ENDOU (PP11) was detected in 66.7% of analyzed mucinous cystadenocarcinomas, 57.1% of serous cystadenocarcinomas, but not in normal ovaries, 47% of breast cancers and 38% of all testicular and gastric cancers (Inaba et al, 1980;Inaba et al, 1981;Inaba et al, 1982).…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of a prognostic model based on ferroptosis-associated genes in head and neck squamous cancer

Wei

Tian

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Ferroptosis is that under the action of ferrous iron or ester oxygenase, unsaturated fatty acids highly expressed on the cell membrane are catalyzed to undergo lipid peroxidation, thereby inducing cell death. In this study, we used ferroptosis marker genes to identify 3 stable molecular subtypes (C1, C2, C3) with distinct prognostic, mutational, and immune signatures by consensus clustering; TP53, CDKN2A, etc. Have higher mutation frequencies in the three subtypes. C3 has a better prognosis, while the C1 subtype has a worse prognosis. WGCNA is used to identify molecular subtype-related gene modules.After filting, we obtained a total of 540 genes related to the module feature vector (correlation>0.7).We performed univariate COX regression analysis on these genes, and identified a total of 97 genes (p < 0.05) that had a greater impact on prognosis, including 8 ‘‘Risk” and 89 ‘‘Protective” genes. After using lasso regression, we identified 8 genes (ZNF566, ZNF541, TMEM150C, PPAN, PGLYRP4, ENDOU, RPL23 and MALSU1) as ferroptosis-related genes affecting prognosis. The ferroptosis prognosis-related risk score (FPRS) was calculated for each sample in TCGA-HNSC dataset. The results showed that FPRS was negatively correlated with prognosis.The activated pathways in the PFRS-high group mainly include immune-related pathways and invasion-related pathways. We assessed the extent of immune cell infiltration in patients in our TCGA-HNSC cohort by using the expression levels of gene markers in immune cells. The FPRS-high group had a higher level of immune cell infiltration. We found that the expression of immune checkpoints was significantly up-regulated in the FPRS-low group and the FPRS-high group had a higher probability of immune escape and a lower probability of benefiting from immunotherapy. In this work, we constructed a scoring Ferroptosis-related prognostic model that can well reflect risk and positive factors for prognosis in patients with head and neck squamous cell carcinoma. It can be used to guide individualized adjuvant therapy and chemotherapy for patients with head and neck cancer. Therefore, it has a good survival prediction ability and provides an important reference for clinical treatment.

show abstract

Possible new markers in trophoblastic diseases

Cited by 14 publications

References 1 publication

The Tumor Marker Human Placental Protein 11 Is an Endoribonuclease

The Tumor Marker Human Placental Protein 11 Is an Endoribonuclease

Enzyme immunoassay for placental protein 4 (PP4) and its possible diagnostic significance in patients with genital tract cancer

Identification and validation of a prognostic model based on ferroptosis-associated genes in head and neck squamous cancer

Contact Info

Product

Resources

About